Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heaviliy pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis.

e15255 Background: There is no standard of care for APDAC pts who have progressed to a first line chemotherapy (CT) and all investigated drugs have showed only moderate activity and limited efficacy. Nab-P has shown efficacy in combination with G as first line therapy in APDAC in a randomised phase III trial and it seems to be active in G resistant pts. Methods: APDAC pts who received off-label combination of nab-P 125 mg/m2 and G 1000 mg/m2 on days 1, 8, and 15 of a 28 day cycle as 2ndor further line of treatment in five Italian centers were retrospectively analyzed. We evaluated activity in terms of Disease Control Rate (DCR: Stable Disease + Partial Response + Complete Response, SD+PR+CR), efficacy (Progression Free Survival, PFS and Overall Survival, OS) and safety. Results: 34 pts (M/F: 20/14) median age of 60 (range 41-83) and ECOG Performance Status of 0/1/2: 8/17/9 respectively, were evaluated in our analysis. Median CA19.9 baseline level was 892 U/I, 17.6% pts had biliary stent, 21 pts (61.8%) ha...